HER2+ Breast & Stomach Cancer Treatment Option | Herceptin® …
网页Herceptin HYLECTA: What it treats Adjuvant Breast Cancer. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the …
Herceptin Treatment Schedule
网页Read about the treatment schedule for Herceptin® (trastuzumab), a treatment for HER2+ early breast cancer. See Full Safety and Boxed Warnings for more information. For US Healthcare Professionals
Metastatic Breast Cancer - herceptin
网页Learn about the specific types of HER2+ cancers that Herceptin® (trastuzumab) treats and its history of treating 2.3 million people over 20 years. See full safety & Boxed Warnings for more information.
Potential Side Effects of Herceptin
网页Learn about potential side effects when using Herceptin® (trastuzumab) as a HER2+ metastatic breast cancer treatment. Read the Important Safety Information (ISI) for Herceptin® (trastuzumab). See full safety & Boxed Warnings for more information.
Preparing for Treatment for HER2+ Early Breast Cancer - herceptin
网页Find information about preparing for Herceptin® (trastuzumab) infusion treatment for HER2+ early breast cancer. See full safety & Boxed Warnings for more information.
How Herceptin is Thought to Work
网页Herceptin administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of Herceptin administration. Interrupt Herceptin infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve.
How Herceptin is Thought to Work
网页Herceptin HYLECTA: What it treats Adjuvant Breast Cancer. HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the …
Herceptin® (trastuzumab) Dosing in HER2+ Adjuvant Breast Cancer
网页One week following the last weekly dose of Herceptin, administer Herceptin at 6 mg/kg as an intravenous infusion over 30-90 minutes every three weeks As a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:
What Herceptin® (trastuzumab) Treats | HER2+ Adjuvant Breast …
网页Herceptin administration can result in serious and fatal infusion reactions; Symptoms usually occur during or within 24 hours of Herceptin administration; Interrupt Herceptin infusion for dyspnea or clinically significant hypotension; Monitor …
HER2+ Adjuvant Breast Cancer | Herceptin® (trastuzumab)
网页Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for Herceptin treatment and any potential adverse effects on the breastfed child from Herceptin or from the underlying maternal condition
- 某些结果已被删除
跳至内容